Enalapril/nitrendipine

Drug Profile

Enalapril/nitrendipine

Alternative Names: Eneas; Nitrendipine/enalapril

Latest Information Update: 15 Jul 2015

Price : $50

At a glance

  • Originator Vita
  • Class Antihypertensives; Dihydropyridines; Dipeptides; Small molecules
  • Mechanism of Action ACE inhibitors; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Essential hypertension

Most Recent Events

  • 01 Oct 2013 Warner Chilcott has been acquired and merged into Actavis Inc
  • 30 Oct 2009 Warner Chilcott has acquired the global pharmaceutical business of Procter & Gamble
  • 28 Jul 2005 Fournier-Pharma has been acquired by Solvay
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top